G(M3) Ganglioside

A ganglioside present in abnormally large amounts in the brain and liver due to a deficient biosynthetic enzyme, G(M3):UDP-N-acetylgalactosaminyltransferase. Deficiency of this enzyme prevents the formation of G(M2) ganglioside from G(M3) ganglioside and is the cause of an anabolic sphingolipidosis.

Also Known As:

Networked: 225 relevant articles (3 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kabayama, Kazuya: 8 articles (01/2020 - 02/2002)
2.	Carr, Adriana: 8 articles (06/2019 - 01/2011)
3.	Blanco, Rancés: 7 articles (06/2019 - 01/2011)
4.	Kim, Cheorl-Ho: 7 articles (01/2018 - 07/2006)
5.	Lee, Young-Choon: 7 articles (01/2018 - 07/2006)
6.	Rengifo, Charles E: 7 articles (01/2015 - 01/2011)
7.	Rengifo, Enrique: 7 articles (01/2015 - 10/2004)
8.	Inokuchi, Jin-Ichi: 6 articles (01/2022 - 01/2005)
9.	Paller, Amy S: 6 articles (01/2018 - 12/2006)
10.	Cedeño, Mercedes: 6 articles (01/2015 - 01/2011)

Related Diseases

1.	Experimental Melanoma 07/15/1994 - "Murine B16 melanoma expresses the ganglioside GM3. " 03/29/1994 - "Mouse B16 melanoma cell line, GM-95 (formerly designated as MEC-4), deficient in sialyllactosylceramide was examined for its primary defect. " 12/01/2008 - "Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge." 05/04/2007 - "Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells." 04/10/1998 - "Mouse melanoma B16 cells are characterized by the predominant presence of ganglioside GM3 and adhere to lactosylceramide- or Gg3-coated plates through interaction of GM3 with lactosylceramide or Gg3, whereby not only adhesion but also spreading and enhancement of cell motility occur (Kojima, N., Hakomori, S. "
2.	Mucolipidoses (Sialidosis) 01/01/1991 - "This fraction was highly specific for the hydrolysis of sialic acid from GM3 ganglioside, and was equally effective in fibroblasts from patients with mucolipidosis IV and in fibroblasts from controls." 05/15/1989 - "Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties." 01/04/1983 - "In sialidosis with partial beta-galactosidase deficiency, the sialidases of the lysosomes showed 3-5% activity toward hydrophilic substrates and 25% activity toward GM3 ganglioside as compared with sialidase activities of the controls. " 05/15/1989 - "In fibroblasts from patients with mucolipidosis IV (ML IV), both the Triton X-100- and the cholate-stimulated ganglioside GM3 sialidase activities were in the range of normal controls. " 05/15/1989 - "In fibroblasts from sialidosis patients, the cholate-stimulated ganglioside GM3 sialidase activity, but not that of the Triton-activated enzyme, was profoundly diminished. "
3.	Lewis Lung Carcinoma 01/01/1993 - "Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line." 07/01/2006 - "Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells." 07/01/2006 - "To investigate the significance of the ganglioside GM3 in cancer malignancy, we established GM3-reconstituted cells by transfecting the cDNA of GM3 synthase into a GM3-deficient subclone of the 3LL Lewis lung carcinoma cell line (Uemura, S. " 10/15/1990 - "Treatment of Lewis lung carcinoma cells with 5 microM D-PDMP resulted in a time-dependent marked decrease in levels of all cellular GSLs (glucosylceramide, lactosylceramide, ceramide trihexoside, globoside, and ganglioside GM3). "
4.	Neoplasms (Cancer) 08/01/2007 - "The study suggested that GM3 ganglioside may have a crucial role in "downregulation" of the metastatic potential of bovine urothelial cancers." 10/01/2022 - "One-Pot Enzymatic Synthesis and Biological Evaluation of Ganglioside GM3 Derivatives as Potential Cancer Immunotherapeutics." 10/01/2021 - "These results suggest that the endothelial ganglioside GM3 regulates tumor angiogenesis by suppressing cellular invasion and oxidative stress tolerance in endothelial cells." 10/01/2021 - "Endothelial ganglioside GM3 regulates angiogenesis in solid tumors." 03/01/2019 - "Chemoenzymatically synthesized ganglioside GM3 analogues with inhibitory effects on tumor cell growth and migration."
5.	Insulin Resistance 05/01/2014 - "Ganglioside GM3 mediates adipocyte insulin resistance, but the role of GM3 in diabetic wound healing, a major cause of morbidity, is unclear. " 03/01/2008 - "The ganglioside GM3 has recently shown to be a negative regulator of insulin sensitivity. " 03/18/2003 - "Enhanced insulin sensitivity in mice lacking ganglioside GM3." 02/01/2002 - "Ganglioside GM3 participates in the pathological conditions of insulin resistance." 01/01/2021 - "Computational docking analysis disclosed the possible stabilizing effect of PFOA on the complex between InsR and GM3 ganglioside, previously shown to be associated with the low grade chronic inflammation-related insulin resistance. "

Related Drugs and Biologics

1.	N-Acetylneuraminic Acid (Sialic Acid)
2.	Glucosylceramides (Glucocerebrosides)
3.	Vaccines
4.	CDw17 antigen (lactosylceramide)
5.	RV 538 (PDMP)
6.	ceramide trihexoside
7.	Glycolipids
8.	Monoclonal Antibodies
9.	Lipids
10.	haematoside synthetase

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics